COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.14 -0.39 (-3.38%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD ↗

April 12, 2024

The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.

Via Talk Markets

Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday ↗

April 01, 2024

U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday.

Via Benzinga

Topics Stocks

March Recap: Largest Psychedelic Drug Stocks Up Another 5% ↗

March 30, 2024

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.

Via Talk Markets

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗

March 30, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Preview For Compass Pathways ↗

February 28, 2024

Via Benzinga

Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America? ↗

February 02, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline ↗

March 29, 2024

Via Benzinga

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

The Next Great Biotech Boom Has Arrived

March 19, 2024

EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement ↗

March 13, 2024

Via Benzinga

Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week ↗

March 11, 2024

The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.

Via Talk Markets

MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials ↗

March 07, 2024

Via Benzinga

Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More ↗

March 06, 2024

Via Benzinga

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗

March 05, 2024

All three have exciting programs on the way.

Via The Motley Fool

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD ↗

March 01, 2024

The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.

Via Talk Markets

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript ↗

February 29, 2024

CMPS earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment ↗

February 29, 2024

Via Benzinga

Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream' ↗

February 29, 2024

Via Benzinga

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

Penny Power Players: 3 Stocks to Watch in the Microcap Arena ↗

February 27, 2024

Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out.

Via InvestorPlace

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. ↗

February 19, 2024

The lofty target is closer to being within reach than it may seem at first.

Via The Motley Fool

Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex ↗

February 18, 2024

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...

Via Talk Markets

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Why Is MindMed (MNMD) Stock Up 8% Today? ↗

February 12, 2024

MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.

Via InvestorPlace

5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗

January 30, 2024

The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.

Via Talk Markets

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.